Login to Your Account

Europe's Health Sector Pushes Review of New Therapies' Value

By Nuala Moran
BioWorld International Corresponden

Wednesday, December 14, 2011
LONDON – The health care sector in Europe has joined forces to push for industry involvement in the health technology assessments (HTA) that are increasingly being carried out to measure the added-value of new therapies, and then used as the basis of deciding whether or not to pay for them.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription